Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Viral-specific T-lymphocytes (f42421)
- Development stage
- Unknown
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Viral-specific T-lymphocytes (VSTs) are an investigational adoptive cellular therapy being developed by Jessie L. Alexander at the University of Alabama at Birmingham (UAB) for the treatment of refractory adenovirus and cytomegalovirus (CMV) infections. This therapy is specifically designed for immunocompromised patients, such as those who have undergone hematopoietic cell transplantation (HCT) or solid organ transplantation (SOT). The manufacturing process utilizes the Miltenyi Biotec CliniMACS Cytokine Capture System (CCS) to isolate donor-derived T cells that secrete interferon-gamma (IFN-gamma) upon stimulation with specific viral antigens. By enriching for these functional, virus-reactive effector cells from partially HLA-matched donors, the therapy aims to rapidly restore cellular immunity and clear persistent or refractory viremia in patients with compromised immune systems.
- Other names
- Adenovirus Specific T-LymphocytesCytomegalovirus Specific T-LymphocytesViral Specific T-Cells for Adenovirus or CMVCCS-VSTs
02
Targets
HAdV (Human adenovirus)pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)HLA class I/II molecules presenting Epstein–Barr virus-derived peptide antigens
Beyond the preview
Go deeper on Viral-specific T-lymphocytes (f42421).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viral-specific T-lymphocytes (f42421).